113 related articles for article (PubMed ID: 23996078)
1. A pharmacometric approach to investigate the impact of methylxanthine abstinence and caffeine consumption on CYP1A2 activity.
Perera V; Gross AS; Forrest A; Landersdorfer CB; Xu H; Ait-Oudhia S; McLachlan AJ
Drug Metab Dispos; 2013 Nov; 41(11):1957-66. PubMed ID: 23996078
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
Perera V; Gross AS; Xu H; McLachlan AJ
J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
[TBL] [Abstract][Full Text] [Related]
3. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma.
Perera V; Gross AS; McLachlan AJ
Biomed Chromatogr; 2010 Oct; 24(10):1136-44. PubMed ID: 20853468
[TBL] [Abstract][Full Text] [Related]
4. Effect of sodium tanshinone II A sulfonate on the activity of CYP1A2 in healthy volunteers.
Chen Y; Tu JH; He YJ; Zhang W; Wang G; Tan ZR; Zhou G; Fan L; Zhou HH
Xenobiotica; 2009 Jul; 39(7):508-13. PubMed ID: 19534587
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans.
Michaud V; Mouksassi MS; Labbé L; Bélanger PM; Ferron LA; Gilbert M; Grech-Bélanger O; Turgeon J
Ther Drug Monit; 2006 Dec; 28(6):779-83. PubMed ID: 17164694
[TBL] [Abstract][Full Text] [Related]
6. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
[TBL] [Abstract][Full Text] [Related]
7. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio.
Doude van Troostwijk LJ; Koopmans RP; Guchelaar HJ
Fundam Clin Pharmacol; 2003 Jun; 17(3):355-62. PubMed ID: 12803575
[TBL] [Abstract][Full Text] [Related]
8. Omeprazole weakly inhibits CYP1A2 activity in man.
Rost KL; Fuhr U; Thomsen T; Zaigler M; Brockmöller J; Bohnemeier H; Roots I
Int J Clin Pharmacol Ther; 1999 Nov; 37(11):567-74. PubMed ID: 10584979
[TBL] [Abstract][Full Text] [Related]
9. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance.
Spigset O; Hägg S; Söderström E; Dahlqvist R
Eur J Clin Pharmacol; 1999 Feb; 54(12):943-6. PubMed ID: 10192755
[TBL] [Abstract][Full Text] [Related]
10. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
[TBL] [Abstract][Full Text] [Related]
11. Differences in caffeine and paraxanthine metabolism between human and murine CYP1A2.
Labedzki A; Buters J; Jabrane W; Fuhr U
Biochem Pharmacol; 2002 Jun; 63(12):2159-67. PubMed ID: 12110375
[TBL] [Abstract][Full Text] [Related]
12. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.
Bapiro TE; Sayi J; Hasler JA; Jande M; Rimoy G; Masselle A; Masimirembwa CM
Eur J Clin Pharmacol; 2005 Nov; 61(10):755-61. PubMed ID: 16261361
[TBL] [Abstract][Full Text] [Related]
13. The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained?
Spigset O; Hägg S; Söderström E; Dahlqvist R
Pharmacogenetics; 1999 Jun; 9(3):409-12. PubMed ID: 10471076
[No Abstract] [Full Text] [Related]
14. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking.
Faber MS; Fuhr U
Clin Pharmacol Ther; 2004 Aug; 76(2):178-84. PubMed ID: 15289794
[TBL] [Abstract][Full Text] [Related]
15. Validation of urine caffeine metabolite ratios with use of stable isotope-labeled caffeine clearance.
Denaro CP; Wilson M; Jacob P; Benowitz NL
Clin Pharmacol Ther; 1996 Mar; 59(3):284-96. PubMed ID: 8653991
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.
Zandvliet AS; Huitema AD; de Jonge ME; den Hoed R; Sparidans RW; Hendriks VM; van den Brink W; van Ree JM; Beijnen JH
Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):71-9. PubMed ID: 15667599
[TBL] [Abstract][Full Text] [Related]
17. Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping.
Koch JP; ten Tusscher GW; Koppe JG; Guchelaar HJ
Biomed Chromatogr; 1999 Jun; 13(4):309-14. PubMed ID: 10416066
[TBL] [Abstract][Full Text] [Related]
18. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
Lu JF; Yi T; Cao XM; Zhuo HT; Ling SS
Yao Xue Xue Bao; 1997 Nov; 32(11):813-8. PubMed ID: 11596199
[TBL] [Abstract][Full Text] [Related]
19. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
McQuilkin SH; Nierenberg DW; Bresnick E
Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):139-46. PubMed ID: 7742721
[TBL] [Abstract][Full Text] [Related]
20. Measurement of CYP1A2 activity: a focus on caffeine as a probe.
Perera V; Gross AS; McLachlan AJ
Curr Drug Metab; 2012 Jun; 13(5):667-78. PubMed ID: 22554278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
